Key facts
- This page summarizes Christopher Astle's Form 4 filing for Zymeworks Inc. (ZYME).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 08 Jan 2024, 18:14.
Christopher Astle - 05 Jan 2024 Form 4 Insider Report for Zymeworks Inc. (ZYME)
- Reporting relationship
- SVP & Chief Financial Officer
- Issuer ticker
- ZYME
- Reported as of
- 05 Jan 2024
- Net transaction value
- -$64,656
- SEC form
- 4
- Accepted by SEC
- 08 Jan 2024, 18:14:29 UTC
- Prior SEC filing
- 11 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Dex, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christopher Astle filed Form 4 for Zymeworks Inc. (ZYME) on 08 Jan 2024.
Change
- Previous filing in this sequence was filed on 11 Dec 2023.
- Current net transaction value: -$64,656.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZYME
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +10,500
- Change %
- +526%
- Price
- $0.000000
- Shares after
- 12,497
- Date
- 05 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
ZYME
transaction
Common Stock
Sale
- Transaction value
- $48,606
- Shares
- -4,563
- Change %
- -37%
- Price
- $10.65
- Shares after
- 7,934
- Date
- 05 Jan 2024
- Ownership
- Direct
- Footnotes
- F2, F3
ZYME
transaction
Common Stock
Sale
- Transaction value
- $16,050
- Shares
- -1,431
- Change %
- -18%
- Price
- $11.22
- Shares after
- 6,503
- Date
- 08 Jan 2024
- Ownership
- Direct
- Footnotes
- F2, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYME
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -10,500
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 21,000
- Date
- 05 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,500
- Exercise price
- Footnotes
- F5, F6
ZYME
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 05 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $10.56
- Footnotes
- F7
ZYME
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 05 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- Footnotes
- F5, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
Footnote F2
Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
Footnote F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F5
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
Footnote F6
The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
Footnote F7
Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Footnote F8
The RSUs vest in three equal annual installments beginning on January 5, 2025.